Read the main articles published in the last three years, starting in 2018, signed by one or more of our experts:
An update on the pathogenesis of COVID-19 and supposedly rare thrombotic events after vaccination
Therapeutic versus prophylactic anticoagulation for hospital inpatients with COVID-19 and elevated D-dimer concentration: an open, multicenter, randomized, controlled trial
Randomized clinical trial to evaluate a routine complete anticoagulation strategy in patients with coronavirus infection (SARS-CoV2) admitted to the hospital: Rationale and design of Action (AntiCoagulation Coronavirus) – Phase 4
Comparative studies on the anticoagulant profile of branded enoxaparin and a new biosimilar version
Drug Interactions of 257 Antineoplastic Supportive Agents with 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms
Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020
Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
Rationale and design for the Apixaban versus ClopidoGRel study in an aspirin background in a patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial
Guidelines on diagnosis, prevention and treatment of thromboembolic complications at COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Committee on Thrombosis and Hemostasis of the Brazilian Association of Hematology, Hemotherapy and Cell Therapy
Oral anticoagulants and management of cancer-associated thrombosis. Where will we be in 2019?
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for vascular dose and dual pathway inhibition
Porcine Mucosal Heparin Shortage Crisis! What Are the Options?
Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values
Zika and Chikungunya Virus and Risk for Venous Thromboembolism
Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?
Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial
Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide
Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial
Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint
Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again?